JP5002109B2 - セル接着の防止剤としての新規なグアニジノ誘導体 - Google Patents

セル接着の防止剤としての新規なグアニジノ誘導体 Download PDF

Info

Publication number
JP5002109B2
JP5002109B2 JP2002515897A JP2002515897A JP5002109B2 JP 5002109 B2 JP5002109 B2 JP 5002109B2 JP 2002515897 A JP2002515897 A JP 2002515897A JP 2002515897 A JP2002515897 A JP 2002515897A JP 5002109 B2 JP5002109 B2 JP 5002109B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
heteroaryl
formula
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002515897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004505084A5 (https=
JP2004505084A (ja
Inventor
ペイマン アヌシルヴァン
ウィル デイビッド
アール．ガデック トマス
マクダウエル ロバート
グールベスト ジャンフランソワ
リュグゼ ジャンマリー
クノル ヨッヘン
Original Assignee
アヴェンティス ファルマ ドイチェラント ゲーエムベーハー
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アヴェンティス ファルマ ドイチェラント ゲーエムベーハー, ジェネンテック， インコーポレイテッド filed Critical アヴェンティス ファルマ ドイチェラント ゲーエムベーハー
Publication of JP2004505084A publication Critical patent/JP2004505084A/ja
Publication of JP2004505084A5 publication Critical patent/JP2004505084A5/ja
Application granted granted Critical
Publication of JP5002109B2 publication Critical patent/JP5002109B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2002515897A 2000-07-28 2001-07-23 セル接着の防止剤としての新規なグアニジノ誘導体 Expired - Lifetime JP5002109B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00116385.6 2000-07-28
EP00116385A EP1176145A1 (en) 2000-07-28 2000-07-28 Novel guanidino derivatives as inhibitors of cell adhesion
PCT/EP2001/008485 WO2002010168A1 (en) 2000-07-28 2001-07-23 Novel guanidino derivatives as inhibitors of cell adhesion

Publications (3)

Publication Number Publication Date
JP2004505084A JP2004505084A (ja) 2004-02-19
JP2004505084A5 JP2004505084A5 (https=) 2008-07-03
JP5002109B2 true JP5002109B2 (ja) 2012-08-15

Family

ID=8169381

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002515897A Expired - Lifetime JP5002109B2 (ja) 2000-07-28 2001-07-23 セル接着の防止剤としての新規なグアニジノ誘導体

Country Status (7)

Country Link
US (1) US7259159B2 (https=)
EP (2) EP1176145A1 (https=)
JP (1) JP5002109B2 (https=)
AT (1) ATE432934T1 (https=)
AU (1) AU2001278503A1 (https=)
DE (1) DE60138893D1 (https=)
WO (1) WO2002010168A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
FR2786184B1 (fr) * 1998-11-24 2002-09-20 Hoechst Marion Roussel Inc Nouveaux derives du benzofurane, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant

Also Published As

Publication number Publication date
EP1313737A1 (en) 2003-05-28
EP1313737B1 (en) 2009-06-03
WO2002010168A1 (en) 2002-02-07
ATE432934T1 (de) 2009-06-15
US20030203896A1 (en) 2003-10-30
DE60138893D1 (https=) 2009-07-16
US7259159B2 (en) 2007-08-21
EP1176145A1 (en) 2002-01-30
AU2001278503A1 (en) 2002-02-13
JP2004505084A (ja) 2004-02-19

Similar Documents

Publication Publication Date Title
JP4620190B2 (ja) 置換プリン誘導体、その製法、その使用およびそれを含有する組成物
SK9032000A3 (en) Novel acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists
DE60022890T4 (de) Naphthyridine derivate, verfahren zu ihrer herstellung, deren anwendung und sie enthaltende pharmazeutische zusammensetzungen
JP2002501054A (ja) 骨吸収の阻害剤として及び細胞接着の阻害剤としての新規のスルホンアミド誘導体
JP4642242B2 (ja) 細胞接着の阻害剤としての新規のグアニジン誘導体
US6747016B1 (en) Substituted purine derivatives as inhibitors of cell adhesion
JP5002109B2 (ja) セル接着の防止剤としての新規なグアニジノ誘導体
US6762190B2 (en) Thienylalanine derivatives as inhibitors of cell adhesion
JP5143989B2 (ja) ビトロネクチン受容体の新規な拮抗薬誘導体
JP2003532732A5 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080414

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080414

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20080414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111012

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120515

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120521

R150 Certificate of patent or registration of utility model

Ref document number: 5002109

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150525

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term